235 filings
Page 4 of 12
8-K
9fi9rttaxau79h
5 Oct 20
Announces Creation of Clinical Pharmacology Analytics Team
9:06am
8-K
25ss4
1 Oct 20
Regulation FD Disclosure
4:27pm
8-K
xfhgl64io5y
29 Sep 20
Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
8:47am
8-K
06c3b 1b7f2hbxherll
17 Sep 20
Other Events
12:40pm
8-K
uv7w04
1 Sep 20
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
1:27pm
8-K
wmgut3y0d9k w1du5ep
27 Aug 20
Other Events
11:19am
8-K
clhhf17gywtssu
12 Aug 20
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
8:46am
8-K
4c5zx z7t2nvtbmfd5z
5 Aug 20
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
9:18am
8-K
6gg98iio gv7
31 Jul 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K
tys3vvhf
7 Jul 20
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
8:26am
8-K
fv1pnds5xnv4xhf09of
29 Jun 20
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
12:00am
8-K
z64m8h31qr yz
22 Jun 20
Other Events
4:54pm
8-K
pfho1pk2qosogln8lmdr
15 Jun 20
Regulation FD Disclosure
9:22am
8-K
jnoycr
10 Jun 20
Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
5:04pm
8-K
nrmii4e
20 May 20
Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
4:35pm
8-K
r61b554bikvfa2ehh2r
19 May 20
Regulation FD Disclosure
9:51pm
8-K
n22hzyoauaq
19 May 20
Other Events
8:12am
8-K
o62414lt
14 May 20
Other Events
4:15pm
8-K
1nxm zmbh
17 Apr 20
Entry into a Material Definitive Agreement
4:05pm
8-K
ycnc4duefc
30 Mar 20
Other Events
4:05pm